[{"orgOrder":0,"company":"COLOPLAST AS","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Urology","graph2":"Phase II","graph3":"COLOPLAST AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"COLOPLAST AS \/ Coloplast AS","highestDevelopmentStatusID":"8","companyTruncated":"COLOPLAST AS \/ Coloplast AS"}]

Find Clinical Drug Pipeline Developments & Deals by COLOPLAST AS

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Fexofenadine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Nephrolithiasis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 27, 2021

                          Lead Product(s) : Fexofenadine Hydrochloride

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Recipient : Columbia University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank